Federal Research Funding Cuts Already Disrupting Clinical Trials Despite Congressional Reprieve

Congress stepped back from the cliff in February 2026. The House and Senate Appropriations Committees rejected the most severe proposed cuts to federal research funding—a 40% reduction to the National Institutes of Health, a 57% cut to the National Science Foundation, and a 15% cap on indirect costs that would have devastated research institutions. Instead, lawmakers increased NIH funding by roughly 1% to $48.7 billion and trimmed NSF funding by only 3.4%. Scientists exhaled. The appropriations bill passed. It felt like a reprieve.

But the reprieve came too late for thousands of people already enrolled in clinical trials. Between February and April 2025—months before Congress made its final decision—the NIH terminated 694 grants. Of those, approximately 20% were early-career grants, the kind that junior researchers depend on entirely to keep their labs open, pay their teams, and fund their own salaries. The terminations disrupted 383 clinical trials in total, affecting 74,311 individual trial participants. Prevention studies were hit hardest: 123 out of 1,460 prevention trials, or 8.4%, were disrupted—the highest proportion of any category. Treatment trials accounted for 140 disruptions out of 5,909 trials. Sixty drug trials were stopped, along with 15 device trials and six dietary supplement trials.

The damage was not distributed equally. Among early-career researchers whose projects were terminated, 59.8% were women. Of the graduate students and postdoctoral fellows whose training was disrupted, women made up 60.2% of doctoral candidates and 48% of postdocs. Women researchers also had more committed funds at the time of cancellation—57.9% compared with 48.2% for men—meaning they lost a proportionally larger share of unrealized scientific work. These early-stage researchers form the foundation of the next generation of scientists. Their disruption now signals a workforce crisis later.

The human cost extended beyond statistics. Dr. Elizabeth M. Jaffee, an oncologist and immunologist at Johns Hopkins who pioneered work in immuno-oncology, described the anguish of facing her patients without answers: she could not tell patients with pancreatic cancer seeking access to promising experimental therapies whether their clinical trials would continue. Trial terminations that lack scientific justification—unexpected safety risks, demonstrated efficacy, or established futility—constitute an ethical breach. The Bethesda Declaration, written in June 2025 by former and current NIH staff and members of the advocacy group 27 UNIHTED, stated plainly that the 2025 grant terminations produced ethically unjustifiable disruptions. They conflicted with commitments made to participants during informed consent. The result is distrust: reduced or no enrollment in future trials, patients losing access to experimental hope, and the scientific enterprise itself damaged.

The broader context makes the disruption even more consequential. Between 2010 and 2016, NIH funding was associated either directly or indirectly with all drug approvals in the United States, with more than 90% of that funding supporting basic research—the foundational work that produced polymerase chain reaction technology and GLP-1-based therapeutics. The Congressional Budget Office estimated that even a 10% reduction in NIH funding would reduce the number of drug candidates available for Phase 1 clinical trials by 4.5%, with the full effect taking 12 years to materialize. Today's funding cuts become tomorrow's gaps in the drug development pipeline.

The delays in fund disbursement, even after Congress approved the appropriations bill, compounded the damage. Money approved in February did not reach researchers' hands immediately. Institutional budgets remained uncertain. Ongoing studies were jeopardized. Trainee support eroded. The scientific community remained in a state of suspended anxiety even after the legislative victory.

Moving forward, alternative funding models are being explored—partnerships between state governments, academic institutions, and the private sector; greater university endowment spending; family office investments; and philanthropic initiatives like SPARC, the Milken Institute Science Philanthropy Accelerator for Research and Collaboration. These sources can help fill gaps, particularly for postdoctoral fellowships and early-career researchers. But alternative funding cannot replace federal investment. Government funding supports the high-risk, long-term, early-stage, and public-interest science that the private sector will not touch. Federal investment remains the backbone. Without it, the research infrastructure upon which scientific progress and patient care depend begins to crack—and the cracks are already visible.